# TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma

> **NCT07189195** · PHASE1 · RECRUITING · sponsor: **University of California, Davis** · enrollment: 52 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- Metastatic Pancreatic Adenocarcinoma
- Refractory Pancreatic Adenocarcinoma
- Stage III Pancreatic Cancer AJCC v8
- Stage IV Pancreatic Cancer AJCC v8
- Unresectable Malignant Solid Neoplasm
- Unresectable Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** TR-002

## Key facts

- **NCT ID:** NCT07189195
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-07
- **Primary completion:** 2029-11-07
- **Final completion:** 2030-02-07
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07189195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07189195, "TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07189195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*